EVUSHELD COVID-19 Treatment Available for Moderately to Severely Immunocompromised Individuals

Provider members should note the availability of COVID-19 prophylactic treatments for individuals in their care who are moderately to severely immunocompromised. EVUSHELD™, a monoclonal antibody, is authorized as pre-exposure prophylaxis to prevent COVID-19 in people moderately to severely immunocompromised.

EVUSHELD™ can also be used by those for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) or its component(s). Data suggests that EVUSHELD™ could have decreased efficacy against the Omicron BA.4.6, BF.7, and BA.2.75 sublineages with substitutions at spike protein 346.

Members should consult the Centers for Disease Control and Prevention (CDC) website for clinical and operational information, as well as details on the treatment's interaction with COVID-19 variants and timing of treatments.

Contact: Meg Everett, meverett@leadingageny.org, 518-867-8871